5244042025-01-012025-03-315244042025-03-315244042024-03-315244042024-04-012025-03-315244042025-01-012025-03-31in-capmkt:OtherExpenses1Member5244042024-04-012025-03-31in-capmkt:OtherExpenses1Member5244042025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15244042025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15244042025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026MARKSANS PHARMA LIMITEDMain BoardEquity2024-04-012025-03-312025-05-192025-05-08INRLakhsQuarterlyFourth quarterSingle segmentPharmaceutical Formulation2025-05-1918:30:002025-05-1919:05:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated70845700016519000724976000188075000160964000-2381800097217000343500022744000160265000608882000116094000011609400024277000109100025368000090726000000090726000264810001172070000000453160001220022Current tax include Current tax for earlier period <BR> <BR> The audited consolidated financial results for the year ended 31 March 2025 has been prepared on the basis of the <BR> consolidated annual financial statements in accordance with the Indian Accounting Standards (Ind AS) as notified <BR> under the Companies (Indian Accounting Standards) Rules 2015 (as amended) specified under section 133 of the <BR> Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure <BR> Requirements) Regulations, 2015 ('the Regulation'), as amended were reviewed and recommended by the Audit <BR> Committee and approved by the Board of Directors at their respective meeting held on May 19, 2025. The Statutory Auditors of the Company have expressed an unmodified opinion on the audited consolidated financial results for the year ended 31 March 2025. <BR> <BR> The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year-to-date figures upto 31 December for respective years which were subject to limited review. <BR> <BR> The Group's activities comprise of manufacturing pharmaceutical formulation and trading in pharmaceutical <BR> products. The Group has only one reportable segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating <BR> Segments'. <BR> <BR> The Board of Directors in the meeting held on 19 May 2025 have recommended final dividend of 0.80 per equity <BR> share of 1 each 80 for the Financial Year 2024-25. <BR> <BR> The above unaudited consolidated financials results are available on the Company's website <BR> (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE <BR> (www.nseindia.com), where the shares of the Company are listed.2024-04-012025-03-31AuditedConsolidated2622845000703760002693221000753023000574477000-183758000350299000116600008338600060016700021892540005039670000503967000128590000-72420001213480000382619000000038261900048047000430666000000045316000108.48.4008.48.4Other Expenses160265000Other Expenses600167000579478000900000040928000361554000181090000035710003571000111100021760000103551100084551600074200054004300049578600020842300003557000124855100012260000977940002204121000003239632000453160002421596000246691200022470000248938200002633290002633290005920000366200027291100023085000363300030206600030569900059141000387925000580260001447000299410004773390007502500003239632000Other Intangible Asset includes Right of use of asset of Rs. 3,069.31 <BR> Other current financial liabilities include Lease Liabilities Rs. 354.9211660000-195467000-777900000-16159000-61000-889000-3140000323740000134800000833860000-782000116900036650000-4877000030197000040060000-661000060530000-171404000332563000000125899000020666400000000000124900017291900000000000000000000033797000088864000-4900900000000000060060000295650002719000023850000-6514600092509000092509000403277000495786000Remeasurements of the net defined benefit liabilities/assets-686000-686000Remeasurements of the net defined benefit liabilities/assets-402000-402000-173000-101000Foreign currency translation reserve2699400026994000Foreign currency translation reserve4834800048348000002648100048047000AuditedtrueM S K A & Associatestrue2027-07-31